Clinical trial
Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia
NCT07578558 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia
- Lead sponsor
- ImmunityBio, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 6, 2026
- Completion date
- October 4, 2027
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
critical illness, immunosuppression, lymphopenia, sepsis, septic shock